Transaction DateRecipientSharesTypePriceValue
Catabasis Pharmaceuticals
Catabasis Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Catabasis Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is edasalonexent, which is intended for the treatment of Duchenne muscular dystrophy.

Ticker: CATB
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1454789
Employees: 27
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags